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Background:  Atherosclerosis is increasingly recognized as an inflammatory process. We utilize psoriasis (PSO), a chronic inflammatory 
skin condition associated with increased cardiovascular disease (CVD), to study inflammatory atherogenesis. [18F]-fluorodeoxyglucose 
(FDG) PET/CT accurately detects vascular inflammation (VI) in vivo. Here, we present data from a well-phenotyped cohort in an ongoing 
cohort study using PSO as a model to study VI.
methods:   Participants with PSO (N=86) were given 10mCi IV 18-FDG and imaged using a Siemens Biograph PET/CT scanner. 
Standardized Uptake Value (SUV) was obtained for arterial and venous FDG uptake using dedicated image analysis software (Philips 
Healthcare). Our outcome was the target-to-background Ratio (TBR) by PET/CT.
results:  Our study cohort was middle aged (mean 51±13 years) with mild to moderate PSO and low CVD risk (median FRS 4, IQR 
2-7). VI by TBR was high in PSO (mean 1.8±0.3) when compared to published values for CAD (mean 1.6). PSO severity related to VI, as 
did known and novel CVD risk factors (Table 1). BMI, waist-to-hip ratio (WHR) and Homeostasis Model Assessment-Insulin Resistance 
(HOMA-IR) showed the strongest association with VI even after adjustment for CVD risk factors. (BMI β 0.47, p<0.001; WHR β 0.28, 
p=0.03 & HOMA-IR β 0.29, p<0.01).
conclusion:  VI in PSO relates with known CVD risk factors. The strong association between VI and cardiometabolic parameters suggests 
that insulin resistance may be an important determinant of CVD risk in PSO.
Characteristics (N=86) Vascular Inflammation (TBR)
Demographics: Beta P (95% CI)
Age (yr) 0.25 0.02
Sex 0.26 0.02
Relevant history:
Hx of Hypertension 0.31 <0.001
Hx of Dyslipidemia 0.27 0.01
Current tobacco use 0.27 0.01
Psoriasis severity:
PASI score 0.36 <0.001
BSA score 0.27 0.01
Anthropometric measures:
Body Mass Index (BMI) 0.53 <0.001
Waist-hip ratio 0.47 <0.001
Systolic blood pressure (mm Hg) 0.33 <0.001
Lab parameters:
HDL (mg/dl) -0.30 <0.001
HDL particle number -0.23 0.02
LDL particle size -0.38 <0.001
Apolipoprotein A1 (mg/dl) -0.30 0.01
Cholesterol efflux capacity -0.28 0.01
Metabolic assessment:
Insulin (IU/ml) 0.50 <0.001
C-peptide (ng/ml) 0.42 <0.001
HOMA-IR 0.40 <0.001
Beta - Standardized regression co-efficient; TBR - Target-to-Background Ratio
PASI - Psoriasis Area Severity Index; BSA - Body Surface Area
HDL - High density lipoprotein; LDL - Low density lipoprotein
HOMA-IR - Homeostasis Model Assessment-Insulin Resistance
